gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Breast Cancer (Systemic and Supportive Therapy)

Meeting Abstract (OP023)

HER2 expression in disseminated tumor cells and corresponding primary tumors of primary breast cancer patients

Fehm T, Bachmann R, Pergola G, Wallwiener D, Vogel U, Solomayer E, Becker S
Meeting Abstract (OP024)

Significant survival benefit of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: results from 979 women enrolled in the ARNO 95 trial

Kaufmann M, Jonat W
Meeting Abstract (OP025)

Lymphedema inbreast cancer patients - Consensus recommendations for the postoperative management of breast cancer patients

Seifart U, Albert U, Heim ME, Hübner J, Jungkunz W, Prokein R, Rick O, Hoffmann A, Engenhart-Cabillic R, Kopp I, Wagner U, Kalder M
Meeting Abstract (OP026)

Molecular risk estimation and adjuvant chemotherapy in node-negative breast cancer patients - a status report of the prospective clinical trial NNBC 3-Europe

Paepke D, Herbst F, Annecke K, Gaskill N, Sweep F, Augustin D, Meisner C, Schmidt M, Schmitt M, Jaenicke F, Harbeck N, Thomssen C
Meeting Abstract (OP027)

Prescription Pattern of Aromatase Inhibitors for the Adjuvant Therapy of Breast Cancer in Germany – Results of the Second Survey Among Gynecologists and Medical Internists

Lüftner D, Scheller J, Henschke P, Possinger K
Meeting Abstract (PO028)

Chemotherapy induced nausea and vomitus (CINV) depends on pharmacogenetisc of the 5-HT-3-Receptor

Kollmansberger B, Lux MP, Beckmann K, Schrauder M, Strissel P, Strick R, Beckmann MW, Fasching PA
Meeting Abstract (PO029)

Long term follow up of sequential dose dense chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in breast cancer patients with 4-9 positive lymph nodes: final results of a phase I/II study

Möbus V, Hauser N, Kurbacher C, Lück H, Thomssen C, Nitz U, Kreienberg R, Untch M
Meeting Abstract (PO030)

Adjuvant chemotherapy of brest cancer: A comparison of 4 standardschemes with regard to praciticability/feasibility and toxicity. An evaluation of the quality assurance project Gynaecological Oncology

Henning K
Meeting Abstract (PO031)

Randomized controlled trial of the feasibility and effects of a structural training program in the rehabilitation of breast cancer patients with fatigue

Elsner von der Malsburg M, Heim M, Niklas A
Meeting Abstract (PO032)

Sorafenib (BAY 43-9006) in patients with metastatic breast cancer - a Phase II multicentre open trial

Loibl S, Bianchi G, Zamagni C, Ardizzoni A, Raab G, Siena S, Wolf C, Westermeier T, Bergamini L, Gianni L, Kaufmann M
Meeting Abstract (PO033)

Darbepoetin alfa as primary prophylaxis of anaemia in breast cancer patients treated preoperatively with Docetaxel, Doxorubicin, Cyclophosphamide

Marquardt F, Loibl S, von Minckwitz G, Kaufmann M
Meeting Abstract (PO034)

Physicians’ Treatment Strategies in Breast Cancer Chemotherapy: The BEAM Drug Utilization Study in Germany

Bauknecht T, Helsberg K, Kessler F, Langer F, Nicolay C, Jackisch C
Meeting Abstract (PO035)

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor–positive breast cancer in premenopausal patients: a randomised, trial (GABG trial IV-A-93)

Vescia S, Graf E, Geberth M, Eiermann W, Jonat W, Conrad B, Brunnert K, Gerber B, Kaufmann M, von Minckwitz G
Meeting Abstract (PO036)

Multi-center Validation of a Gene Expression Based Prognostic Signature in Lymph Node-Negative Primary Breast Cancer

Schmitt M, Foekens JA, Atkins D, Zhang Y, Sweep FCG, Harbeck N, Paradiso A, Cufer T, Klijn J, Wang Y
Meeting Abstract (PO037)

Capecitabine (Xeloda®) in the therapy of metastatic breast cancer

Eschenburg H
Meeting Abstract (PO038)

The combination of mitomycin, 5-fluorouracil and folinate (MiFoFU) is an effective and tolerable chemotherapy regimen in the palliative treatment of patients with metastatic breast cancer and reduced performance

Eichbaum MHR, Gast AS, Bruckner T, Schneeweiss A, Sohn C
Meeting Abstract (PO039)

Case Management as Cross-Sectoral Health Care Provision for Women with Breast Cancer

Thorenz A, Rottscheidt C
Meeting Abstract (PO040)

Integration of lymphedema care in long term follow up for breast cancer patients

Bani M, Eder I, Bani H, Engel J, Lux MP, Allali F, Kreis H, Beckmann K, Breuel C, Beckmann MW, Fasching PA
Meeting Abstract (PO041)

The fate of disseminated tumor cells in bone marrow of primary breast cancer patients after adjuvant systemic therapy

Becker S, Pergola G, Wallwiener D, Solomayer E, Fehm T
Meeting Abstract (PO042)

Benefit from participation in clinical trials

Genss EM, Janni W, Kiechle M, Sommer H, Rack B, Gauger K, Heinrigs M, Steinfeld D, Augustin D, Simon W, Harbeck N, Strobl B, Dian D, Friese K
Meeting Abstract (PO043)

Retrospective analysis of the efficacy of fulvestrant therapy in patients with heavily pretreated metastatic breast cancer

Beau U, Schumann C, Strauß HG, Bojara G, Grosse R, Thomssen C
Meeting Abstract (PO044)

MiX – first results of the ongoing prospective, multi-centre, phase II study

Lux MP, Weiß J, Sommer H, Scharl A, Beckmann K, Kreis H, Beckmann MW, Fasching PA
Meeting Abstract (PO045)

Long-Term Survival with Metastatic Breast Cancer: First Results of a Retrospective Analysis of Patients Treated at the West German Cancer Center (University of Essen Medical School)

Seeber S, Pohlkamp C, Welt A, Walter C, Trarbach T, Lehnerdt C, Hense J, Hügle U, Scheulen ME
Meeting Abstract (PO046)

Anemia therapy with Epoetin beta in adjuvant breast cancer treatment and evaluation of transferrinsaturation (TSAT)

Tessen HW, Nettelnbreker EM, Hesse A, Busch C
Meeting Abstract (PO047)

First analysis of the event-free survival of the GeparDuo-study: neoadjuvant doxorubicin / cyclophosphamide followed by docetaxel (AC-Doc) versus dose-dense doxorubicin and docetaxel (ADoc) in breast cancer

Blohmer JU, Kaufmann M, Eiermann W, Schütte M, Hilfrich J, Gerber B, Eidtmann H, Lampe D, Jackisch C, du Bois A, Loibl S, Zuna I
Meeting Abstract (PE048)

Totally Implantable Venous Access Port Systems for Patients Receiving Chemotherapy for Gynecological or Breast Malignancies: a Prospective Clinical Trial Examining the Safety, Efficacy and Impact on Quality of Life

Kreis H, Löhberg C, Lux MP, Beckmann K, Ackermann S, Lang W, Beckmann MW, Fasching PA
Meeting Abstract (PE049)

Fulvestrant (Faslodex®) – Outcomes of the Expanded Access Programme (EAP) with ZD9238 (Fulvestrant) in Germany for postmenopausal patients with hormone sensitive, metastatic breast cancer after progression under hormone therapy

Gieseking F, Kleeberg U, Jonat W, Illiger HJ, Harbeck N, Lück HJ
Meeting Abstract (PE050)

Outpatient care in metastatic breast cancer

Weide R, Arndt H, Pandorf A, Thomalla J, Heymanns J, Köppler H
Meeting Abstract (PE051)

KoLeDo - a prospective randomized monocenter phase 2 trial investigating 6 x CMF versus 4 x EC chemotherapy in the adjuvant setting of breast cancer therapy in postmenopausal women

Baeuerle M, Berg S, Marre E, Kreienberg R, Volm T
Meeting Abstract (PE052)

Infusion therapy with a high dose of 5-fluorouracil/sodium-folinate in combination with mitomycin C (MMC): a dose escalation study (phase I) for patients with metastatic breast cancer

Tauchert S, Maltaris T, Ertan K, Diedrich K, Schmitt W, Friedrich M
Meeting Abstract (PE053)

Cellular immunotherapy with reactivated autologous Memory T-Cells from bone marrow in late stage breast cancer patients

Schütz F, Ehlert K, Schneeweiss A, Sohn C, Schirrmacher V, Beckhove P